Table 3 Adaptation (note)
Comparison of Live vs.
Inactivated Influenza Vaccine

• Route of administration
• Type of vaccine
• No. of included virus strains
• Vaccine virus strains updated
• Frequency of administration
• Approved age and risk groups
• Interval between two doses recommended for children 6 mos - < 9 yrs who are getting influenza vaccine for first time
• Can be administered to family members or close contacts of immunocompromised persons not requiring a protected environment
• Can be administered to family members or close contacts of immunocompromised persons requiring a protected environment (e.g., hemaotpoietic stem cell transplant recipient)
• Can be administered to family members or close contacts of persons at high risk but not severely immunocompromised
• Can be simultaneously administered with other vaccines
• If not simultaneously administered, can be administered within 4 weeks of another live vaccine
• If not simultaneously administered, can be administered within 4 weeks of an inactivated vaccine

Back

Route of administration

• LAIV: intranasal spray
• TIV: intramuscular injection

Back to Top

Type of vaccine

• LAIV: live virus
• TIV: killed virus

Back to Top

No. of included virus strains

• LAIV: 3 (2 influenza A, 1 influenza B)
• TIV: 3 (2 influenza A, 1 influenza B)

Back to Top

Vaccine virus strains updated

• LAIV: annually
• TIV: annually

Back to Top

Frequency of administration

• LAIV: annually
• TIV: annually

Note: Children aged >= 6 months who have never received influenza vaccine before should receive 2 doses.  Those who received only 1 dose in their first year of vaccination should receive 2 doses in the following year.

Back to Top

Approved age and risk groups

• LAIV: Healthy persons aged 5-49 yrs (note)
• TIV: Persons aged >= 6 months

Back to Top

Interval between two doses recommended for children 6 mos - < 9 yrs who are getting influenza vaccine for first time

• LAIV: 6-10 weeks
• TIV: 4 weeks

Back to Top

Can be administered to family members or close contacts of immunocompromised persons not requiring a protected environment

• LAIV: Yes
• TIV: Yes

Back to Top

Can be administered to family members or close contacts of immunocompromised persons requiring a protected environment (e.g., hemaotpoietic stem cell transplant recipient)

• LAIV: No
• TIV: Yes

Back to Top

Can be administered to family members or close contacts of persons at high risk but not severely immunocompromised

• LAIV: Yes
• TIV: Yes

Back to Top

Can be simultaneously administered with other vaccines

• LAIV: Yes (no data are available regarding effect on safety or efficacy)
• TIV: Yes (has only been evaluated systematically only among adults with pneumococcal polysaccharide vaccine)

Back to Top

If not simultaneously administered, can be administered within 4 weeks of another live vaccine

• LAIV: Prudent to space 4 weeks apart
• TIV: Yes

Back to Top

If not simultaneously administered, can be administered within 4 weeks of an inactivated vaccine

• LAIV: Yes
• TIV: Yes

Back to Top

Note: This table's format was changed to make it more amenable to use on a PDA screen.